Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.
Haleh RezaeeFariba PourkarimSamira Pourtaghi-AnvarianTaher Entezari-MalekiTouraj Asvadi-KermaniMasoud Nouri-VaskehPublished in: Pharmacology research & perspectives (2021)
Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.
Keyphrases
- coronavirus disease
- drug induced
- sars cov
- respiratory syndrome coronavirus
- adverse drug
- end stage renal disease
- newly diagnosed
- rheumatoid arthritis
- ejection fraction
- emergency department
- peritoneal dialysis
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis patients
- replacement therapy
- patient reported